Ischemic Heart Disease (IHD) Drugs Market Analysis 2024 -2033: Forecasted Market Size, Top Segments, And Largest Region | Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A

The Business Research Company has updated its global market reports, featuring the latest data for 2024 and projections up to 2140

The Business Research Company offers in-depth market insights through Ischemic Heart Disease (IHD) Drugs Global Market Report 2024, providing businesses with a competitive advantage by thoroughly analyzing the market structure, including estimates for numerous segments and sub-segments.

Market Size And Growth Forecast:
The ischemic heart disease (ihd) drugs market size has grown strongly in recent years. It will grow from $6.02 billion in 2023 to $6.36 billion in 2024 at a compound annual growth rate (CAGR) of 5.7%. The growth in the historic period can be attributed to rising global prevalence of ischemic heart disease, increased awareness and diagnostics, changes in lifestyle and dietary patterns, government initiatives for cardiovascular health, collaborations for clinical trials, insurance coverage and reimbursement policies..

The ischemic heart disease (ihd) drugs market size is expected to see steady growth in the next few years. It will grow to $7.57 billion in 2028 at a compound annual growth rate (CAGR) of 4.4%. The growth in the forecast period can be attributed to aging population trends, personalized medicine approaches, emphasis on cardiovascular prevention, global health policies and initiatives, international research collaborations.. Major trends in the forecast period include shift towards precision medicine approaches, focus on novel anti-atherogenic agents, advancements in lipid-lowering therapies, integration of anti-inflammatory agents, development of antithrombotic and antiplatelet drugs..

Get Free Sample Of This Report-
https://www.thebusinessresearchcompany.com/sample.aspx?id=13467&type=smp

Market Segmentation:
The main types of drug classes included in ischemic heart disease (IHD) drugs are anti-dyslipidemic drugs, calcium channel blockers, beta-blockers, angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), vasodilators, and antithrombotic agents. Anti-dyslipidemic drugs are pharmacological agents that target and lower abnormal levels of lipids (such as cholesterol and triglycerides) in the bloodstream to reduce the risk of cardiovascular disease. These are used to treat various classes of disease, including angina pectoris and myocardial infarction, and are used by several end users, such as hospital pharmacies, retail pharmacies, and online pharmacies.

Major Driver - Rising Prevalence Of Obesity And Diabetes Fuels Expansion Of The Ischemic Heart Disease (IHD) Drugs Market
The growing prevalence of obesity and diabetes is expected to propel the growth of the ischemic heart disease (IHD) drugs market going forward. Diabetes is a long-term metabolic disease that causes high blood glucose levels, and obesity is a medical condition characterized by an excessive accumulation of body fat that can negatively impact health. Ischemic heart disease drugs are often used in individuals with obesity and diabetes to manage cardiovascular risk factors such as hypertension and dyslipidemia, mitigating the risk of ischemic heart disease. For instance, in March 2023, according to the World Obesity Federation, a UK-based not-for-profit organization, by 2035, obesity rates are expected to double among boys, reaching 208 million (a 100% increase), and more than double among girls, totaling 175 million (a 125% increase), as reported from 2020 levels. Further, It is estimated that the number of people living with obesity will reach 2.7 billion by 2025. Furthermore, in December 2021, according to the International Diabetes Federation, a US-based intergovernmental organization, diabetes affected 537 million adults (20-79 years old) in 2021, and it is predicted that the number would climb to 643 million people by 2030 and a total of 783 million by 2045. Therefore, the growing prevalence of obesity and diabetes drives the growth of the ischemic heart disease (IHD) drugs market.

Competitive Landscape:
Major companies operating in the ischemic heart disease (ihd) drugs market report are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, GSK PLC, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Viatris Inc., Baxter International Inc., Teva Pharmaceutical Industries Ltd., Sandoz Inc., Sun Pharmaceutical Industries Limited, Dr. Reddy's Laboratories Ltd., Cipla Limited, Lupin Limited, Recordati S.p.A., Zydus Lifesciences Limited, Glenmark Pharmaceuticals Ltd., Aurobindo Pharma Limited, Alembic Pharmaceuticals Ltd., Eagle Pharmaceuticals Inc., Accord Healthcare Limited, Macleods Pharmaceuticals Ltd., WG Critical Care LLC, Novitium Pharma LLC

Get Access To The Full Market Report -
https://www.thebusinessresearchcompany.com/report/ischemic-heart-disease-ihd-drugs-global-market-report

Top Trend - Increasing Focus On Developing Intravenous P2Y12 Platelet Inhibitor To Gain A Competitive Advantage
Major companies operating in the ischemic heart disease (IHD) drugs market are increasing their focus on developing innovative platelet inhibitors, such as intravenous P2Y12 platelet inhibitors, to gain a competitive edge in the market. An intravenous P2Y12 platelet inhibitor is a medication administered directly into the bloodstream to prevent platelet activation and aggregation and reduce the risk of periprocedural myocardial infarction (MI), an ischemic heart disease. For instance, in October 2021, MSN Laboratories Private Limited, an India-based research-based pharmaceutical company, launched CANREAL injection (Cangrelor), the only intravenous P2Y12 platelet inhibitor with rapid onset and offset of platelet inhibition. It was developed to overcome both delayed and prolonged antiplatelet activity. It is a bioequivalent generic drug that is indicated as an adjunct to percutaneous coronary intervention to reduce the risk of myocardial infarction (MI).

The Table Of Content For The Market Report Include:
1. Executive Summary
2. Ischemic Heart Disease (IHD) Drugs Market Characteristics
3. Ischemic Heart Disease (IHD) Drugs Market Trends And Strategies
4. Ischemic Heart Disease (IHD) Drugs Market - Macro Economic Scenario
5. Ischemic Heart Disease (IHD) Drugs Market Size And Growth
…..
27. Ischemic Heart Disease (IHD) Drugs Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix

Contact us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 8897263534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Latest Trending Press Releases: https://www.thebusinessresearchcompany.com/press-release.aspx

About The Business Research Company
The Business Research Company (www.thebusinessresearchcompany.com) is a market intelligence firm that pioneers in company, market, and consumer research. Located globally, TBRC's consultants specialize in various industries including manufacturing, healthcare, financial services, chemicals, and technology. The firm has offices located in the UK, the US, and India, along with a network of proficient researchers in 28 countries.

This release was published on openPR.